ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Switch, Change, Rearrange: Diabetes Medication Transitions, De-presc…

Jennifer Rosselli

S. Twillmann

New Research: Side Effect of GLP1

Susan Brian

An Introduction to Tirzepatide for Weightloss

Susan Brian

Predictors of Poor Response to Semaglutide for Weight Management

Ploutarchos Tzoulis

Etiology of Obesity

Beverly Tchang

Carbohydrate-Insulin Model: A Physiological Perspective on the Obesi…

The Texas Heart Institute

D. Ludwig

Ozempic, Zepbound, and More: Behavioral Interventions & Weight Loss …

Baystate Health

M. Gortakowski, K. Jobbins

Obesity in the Year 2024

Barbara Mcgowan

Diabesity: The True Pandemic of the XXI Century

Rodolfo Galindo

Weight Wellness for the PCP: The Next Generation of Anti-Obesity Med…

University of Texas Southwestern Medical Center

J. Almandoz

FLOW: The First Dedicated CKD Outcomes Trial With a GLP-1 Receptor A…

AdventHealth

R. Pratley

Essential Elements of Outpatient Antibiotic Stewardship

Scripps Health

C. Richardson

The Connection Between Diabetes and Heart Disease

Northwestern Medicine Endocrinology

S. Shah, R. F. Kushner

Outcome of Advanced CKD Without Albuminuria: Impact of SGLT2i and GL…

Heart in Diabetes (HiD)

M. R. Weir

How Do I Prescribe GLP-1 Agonists and to Whom?

Penn Medicine Heart and Vascular Center

J. Flood

Selenium Toxicity: Nail Dystrophy, Hair Loss, and Dietary Supplements

Evidence-Based Hair

J. Donovan

Emerging Treatments for Obesity

Canadian Collaborative Research Network

M. Poddar